^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    UGT1A1*28 + UGT1A1*6

    i
    Other names: UGT1A1, UDP glucuronosyltransferase family 1 member A1, GNT1, UGT1, UDPGT, UGT1A, HUG-BR1, BILIQTL1, UDPGT 1-1
    Entrez ID:
    54658
    Related biomarkers:
    Mutation
    8ms
    A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    cisplatin • etoposide IV • Beleodaq (belinostat)
    8ms
    Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin. (PubMed, Cancer Diagn Progn)
    Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment. Additionally, high AST value and pancreatic head cancer may be risk factors for leukopenia during nal-IRI/FL treatment.
    Journal • Adverse events
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    8ms
    Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights. (PubMed, J Chemother)
    Hence, screening for UGT1A1 polymorphisms before irinotecan-based chemotherapy is recommended to minimize toxicity, whereas liposomes offer the potential to deliver irinotecan with fewer side effects in patients with pancreatic ductal adenocarcinoma. This review presents a comprehensive overview of the effects of genotype-guided dosing of irinotecan on UGT1A1*28 and UGT1A1*6 variants, incorporating pharmacogenomic research, optimal regimens for metastatic colorectal and pancreatic cancer treatment using irinotecan, guidelines for toxicity reduction, and an evaluation of the cost-effectiveness of UGT1A1 genotype testing.
    Review • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    irinotecan
    over2years
    The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. (PubMed, Int J Clin Oncol)
    Based on our findings, the safety and efficacy of mFOLFIRINOX (irinotecan 80 mg/m) in DV patients were comparable with the standard mFOLFIRINOX (irinotecan 150 mg/m) in non-DV patients.
    Retrospective data • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    3years
    Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. (PubMed, Expert Opin Drug Metab Toxicol)
    This approach is likely to improve patient care and reduce healthcare costs. Future large and prospective studies will help to clarify the clinical value of other genetic markers in irinotecan treatment personalization.
    Clinical • Journal • Adverse events
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    irinotecan